Rahul S Bhansali

19PUBLICATIONS
102CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)AutoimmunityMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Jul 10, 2026
LDB1-dependent enhancer connectivity defines T-cell leukemia identities and masks metabolic vulnerabilities.

|Apr 25, 2026
Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy.

|Dec 11, 2025
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Yucai Wang, Melissa C Larson, Steven R Hwang

|Nov 07, 2025
Outcomes for CART as 2L vs 3L vs 4L or beyond in aggressive B-cell lymphoma: real-world evidence from the ABC Consortium.

John S Wang, Brandon L Ellsworth, Megan Melody

|Jul 29, 2025
Real World Outcomes of Patients with Aggressive Lymphoma and Autoimmune Disease Treated with CART.

Nicole J Altomare, Megan M Herr, Nisha M Nair

|Mar 28, 2025
DYRK1A inhibition results in MYC and ERK activation rendering KMT2A-R acute lymphoblastic leukemia cells sensitive to BCL2 inhibition.

V S S Abhinav Ayyadevara, Gerald Wertheim, Shikha Gaur

Pageof 4

Frequent Collaborators

9 joint publications

Reem Karmali

8 joint publications

Stefan K Barta

6 joint publications

Leo I Gordon

6 joint publications

Narendranath Epperla